Pharmacology and pharmacogenetics of chemotherapeutic agents

Cancer Investigation

Volumn 27, Issue 5, 2009, Pages 482-488

  Dawood, Shaheenah ^a   Leyland Jones, Brian ^b  

^a DUBAI HEALTH AUTHORITY   (United Arab Emirates)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

Chemotherapy toxicity; Personalized medicine; Pharmacogenetics; Pharmacokinetics

Indexed keywords

5 FLUORO 2 DEOXYURIDINE MONOPHOSPHATE; 7 ETHYL 10 HYDROXYCAMPTOTHECIN; ACYLTRANSFERASE; AMONAFIDE; ANTIINFECTIVE AGENT; AZATHIOPRINE; CARBOPLATIN; CISPLATIN; DOCETAXEL; DOXORUBICIN; DRUG METABOLITE; ENDOXIFEN; FLUOROURACIL; GEMCITABINE; IRINOTECAN; ISONIAZID; MERCAPTOPURINE; METHOTREXATE; PACLITAXEL; PHOSPHATE; TAMOXIFEN; TAXANE DERIVATIVE; TIOGUANINE; UNCLASSIFIED DRUG; WARFARIN; ANTINEOPLASTIC AGENT;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADVANCED CANCER; AREA UNDER THE CURVE; BREAST CANCER; CLINICAL TRIAL; COLORECTAL TUMOR; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG MECHANISM; DRUG METABOLISM; DRUG RECEPTOR BINDING; GENETIC ANALYSIS; HUMAN; METASTASIS; NEUTROPENIA; PHARMACOGENETICS; PRIORITY JOURNAL; REVIEW; TOXICITY; TUBERCULOSIS; GENETICS; NEOPLASM; PROGNOSIS;

ANTINEOPLASTIC AGENTS; HUMANS; NEOPLASMS; PHARMACOGENETICS; PROGNOSIS;

EID: 67449098636     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.1080/07357900802574660     Document Type: Review

References (37)

1. Bordet, R.; Gautier, S.; Le Louet, H.; et al. Analysis of the direct cost of adverse drug reactions in hospitalized patients. Eur J Clin Pharmacol 2001, 56, 935-941. (Pubitemid 33788573)
2. Evans, W.E.; Relling, M.V. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999, 286, 487-491.
3. Jeffrey, S.; Ross, M.D.; David, P.; et al. Pharmacogenomics. Adv Anat Pathol 2004, 11, 211-220.
4. Lazarou, J.; Pomeranz, B.H.; Corey, P.N. Incidence of adverse drug reactions in hospitalized patients - a meta-analysis of prospective studies. JAMA 1998, 279, 1200-1205. (Pubitemid 28193431)
5. Johnson, J.A.; Bootman, J.L. Drug-related morbidity and mortality. A cost-of-illness model. Arch Intern Med 1995, 155, 1949-1956.
6. Egorin, M.; Echo, D.V.; Olman, E.; et al. Prospective validation of a pharmacologically based dosing scheme for the cisdiamminedichloroplatinum (II) analogue diamminecylobutane dicarboxylato platinum. Cancer Res 1985, 45, 6502.
7. Calvert, A.; Newell, D.; Gumbrell, L.; et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989, 7, 1748.
8. Lichtman, S.M.; Hollis, D.; Miller, A.A.; et al. Prospective evaluation of the relationship of patient age and paclitaxel clinical pharmacology: Cancer and Leukemia Group B (CALGB 9762). J Clin Oncol 2006, 24, 1846-1851.
9. Sachidanadam, R.; Weissman, D.; Schmidt, S.C.; et al. A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature 2001, 409, 928-933.
10. Evans, D.A.; Manley, K.A.; McKusch, V.A.; et al. Genetic control of isoniazid metabolism in man. Br Med J 1960, 2, 485-491.
11. Knight, R.A.; Selin, M.J.; Harris, H.W.; et al. Genetic factors influencing isoniazid blood levels in humans. Trans Conf Chemother Tuberc 1959, 8, 52-56.
12. Evans, D.A. Survey of human acetylator polymorphism in spontaneous disorders. J Med Genet 1984, 21, 243-253.
13. Ratain, M.J.; Mick, R.; Berezin, F.; et al. Paradoxical relationship between acetylator phenotype and amonafide toxicity. Clin Pharmacol Ther 1991, 50, 573-579.
14. Pui, C.-H., Evans, W.E. Acute lymphoblastic leukemia. New Engl J Med 1998, 339, 605-615.
15. Krynetski, E.Y.; Tai, H.L.; Yates, C.R.; et al. Genetic polymorphisms of thiopurine S-methyltransferase: clinical importance and molecular mechanisms. Pharmacogenetics 1996, 6, 279-290.
16. McLeod, H.L.; Coulthard, S.; Thomas, A.E.; et al. Analysis of thiopurinemethyltransferase variant alleles in childhood acute lymphoblastic leukemia. Br J Hematol 1999, 105, 696-700. (Pubitemid 29277028)
17. Pui, C.-H., Relling, M.V.; Cheng Cheng, et al. Thiopurine methyltransferase in acute lymphoblastic leukemia. Blood 2006, 107, 843-844. (Pubitemid 43076417)
18. Molloy, A.M.; Daly, S.; Mills, J.L.; et al. Thermolabile variant of 5,10-methylenetetrahydrofolate reductase associated with low red-cell folates: implications for folate intake recommendations. Lancet 1997, 349, 1591-1593.
19. Franco, R.F.; Simoes, B.P.; Tone, L.G.; et al. The methylenetetrahydrofolate reductase C677T gene polymorphism decreases the risk of childhood acute lymphocytic leukemia. Br J Haematol 2001, 115, 616-618. (Pubitemid 34015653)
20. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet 2005, 365, 1687-1717.
21. Lonning, P.E.; Lien, E.A.; Lundgren, S.; et al. Clinical pharmacokinetics of endocrine agents used in advanced breast cancer. Clin Pharmacokinet 1992, 22, 327-358.
22. Stearns, V.; Johnson, M.D.; Rae, J.M.; et al. Active tamoxifen metabolite plasma concentrations after co administration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 2003, 95, 1758-1764.
23. Osborne, C.K. Tamoxifen in the treatment of breast cancer. N Engl J Med 1998, 339, 1609-1618.
24. Desta, Z.; Ward, B.A.; Soukhova, N.V.; et al. Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D J Pharmacol Exp Ther 2004, 310, 1062-1075.
25. Jin, Y.; Desta, Z.; Stearns, V.; et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 2005, 97, 30-39.
26. Goetz, M.P.; Rae, J.M.; Suman, V.J.; et al. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol 2005, 23, 9312-9318.
27. Iyer, L.; King, C.D.; Whitington, P.F.; et al. Genetic predisposition to themetabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest 1998, 101, 847-854.
28. Heidelberger, C.; Chaudhuri, N.K.; Danneberg, P.; et al. Fluorinated pyrimidines, a new class of tumor-inhibitory compounds. Nature 1957, 179, 663-666.
29. Etienne, M.C.; Lagrange, J.L.; Dassonville, O.; et al. Population study of dihydropyrimidine dehydrogenase in cancer patients. J Clin Oncol 1994, 12, 2248-2253. (Pubitemid 24346691)
30. McLeod, H.L.; Collie-Duguid, E.S.; Vreken, P.; et al. Nomenclature for human DPYD alleles. Pharmacogenetics 1998, 8, 455-459.
31. Lu, A.; Zhang, R.; Diasio, R.B. Dihydropyrimadine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy. Cancer Res 1993, 53, 5433-5438.
32. Raida, M.; Schwabe, W.; Hausler, P.; et al. Prevalence of a common pointmutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5′-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)-related toxicity compared with controls. Clin Cancer Res 2001, 7, 2832-2839.
33. Grem, J.L. 5-Fluorouracil: forty-plus and still ticking. A review of its preclinical and clinical development. Invest New Drugs 2000, 18, 299-313.
34. Leichman, C.G.; Lenz, H.J.; Leichman, L.; et al. Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protractedinfusion fluorouracil and weekly leucovorin. J Clin Oncol 1997, 15, 3223-3229.
35. Horie, N.; Aiba, H.; Oguro, K.; et al. Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5′-terminal regulatory region of the human gene for thymidylate synthase. Cell Struct Funct 1995, 20, 191-197.
36. Marsh, S.; Mckay, J.A.; Cassidy, J.; Mcleod, H.L. Polymorphism in the thymidylate synthase promoter enhancer region in colorectal cancer. Int J Oncol 2001, 19, 383-386.
37. Flochart, D.A. Pharmacogenomics in the endocrine treatment of breast cancer. San Antonio Breast Cancer Symposium, MINI Symposium 4; 2005.